Interpretation of IMI-Industry Guidelines and Ethical Considerations for Myopia Control Report

Authors: Xu Qiong,  Zhao Mingwei
DOI: 10.3760/cma.j.cn115989-20210412-00246
Published 2021-12-10
Cite asChin J Exp Ophthalmol, 2021, 39(12): 1086-1090.

Abstract

Along with the increasing global prevalence of myopia, severer myopia brings concerns about a higher risk of potentially blinding complications.Myopia is becoming one of the major causes of vision impairment and blindness in the world, and the myopia prevention and control has been a focus of the whole society.Management of myopia includes more outdoor activities, medications, orthokeratology, peripheral defocus soft contact lens, progressive addition lenses and bifocal lenses, etc.These methods have raised ethical disputes among regulatory bodies, manufacturers, academics and clinicians, who share an ethical responsibility to ensure that the products used for myopia control are safe and efficacious and that patients understand the benefits and potential risks of such products.The IMIIndustry Guidelines and Ethical Considerations for Myopia Control Report published in 2019 highlights the ethical challenges and provides stakeholders with recommendations and guidelines in decision-making, production development, spreading of research progress, prescribing, financial support and advertising of such treatments.Some common problems in combination with the latest clinical studies and relevant evidence-based guidelines were reviewed and reasonable solutions were recommended in this article.

Key words:

Myopia/prevention and control; Ethical review; Conflict of interest; Industry guidelines

Contributor Information

Xu Qiong

Department of Ophthalmology, Peking University People’s Hospital, Eye Diseases and Optometry Institute, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University Health Science Center, Beijing 100044, China

Zhao Mingwei

Department of Ophthalmology, Peking University People’s Hospital, Eye Diseases and Optometry Institute, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University Health Science Center, Beijing 100044, China

(Read 8 times, 1 visits today)
Updated: December 21, 2021 — 6:46 am